<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556594</url>
  </required_header>
  <id_info>
    <org_study_id>16416</org_study_id>
    <secondary_id>I8R-MC-IGBA</secondary_id>
    <secondary_id>AMG102</secondary_id>
    <nct_id>NCT01556594</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia</brief_title>
  <acronym>AMG102</acronym>
  <official_title>Phase II Study to Investigate the Safety and Efficacy of 2 Dose Levels of a Novel Glucagon Formulation Compared to Commercially Available Glucagon in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Locemia Solutions ULC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, participants with Type 1 diabetes received insulin through an infusion into a
      vein to reduce their blood glucose, and then received nasal glucagon (NG) or glucagon for
      injection under the skin, and their blood glucose was measured for 3 hours.

      The main objective of this study was to evaluate the safety and efficacy of intranasal and
      subcutaneous glucagon (SC) in reversing insulin-induced hypoglycemia in participants with
      type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the study, up to four (4) treatments were administered as a single dose either
      intranasally or subcutaneously to eighteen (18) male or female participants under fasting
      conditions and following the use of insulin to lower blood glucose. The participants were
      assigned at random to a group that received one treatment for each of the 3 study periods.
      The glucagon administrations were separated by approximately 7 calendar days. For 2
      participants, a single dose of 3 mg NG was administered at the 4th period that was separated
      by at least 21 calendar days from the 3rd period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders</measure>
    <time_frame>Pre-dose; 30 minutes following glucagon administration</time_frame>
    <description>Participants with a blood glucose increment of ≥1.5 millimole per liter [mmol/L) within 15 of nadir (5 minutes post dose) and for at least 10 minutes following nadir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With at Least One Adverse Event</measure>
    <time_frame>Within 3 hours post glucagon administration</time_frame>
    <description>Safety and tolerability evaluated through the assessment of adverse events. An AE was defined as any untoward medical occurrence in a clinical investigation subject administered the investigational product and which did not necessarily have a causal relationship with this treatment. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Baseline-Adjusted Glucose</measure>
    <time_frame>Pre-dose; 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose</measure>
    <time_frame>Pre-dose; 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Change From Baseline Concentration (Cmax) of Glucagon</measure>
    <time_frame>Pre-dose; 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon</measure>
    <time_frame>Pre-dose; 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC0-last) of Baseline Adjusted Glucagon</measure>
    <time_frame>Pre-dose; 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Nasal Glucagon 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal glucagon (NG) administered as single dose of 1 milligram (mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal Glucagon 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NG administered as single dose of 2 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Glucagon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucagon solution dose of 1 mg administered as a single subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal Glucagon 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NG administered as single dose of 3 mg (composed of one dose of 1 mg NG immediately followed by one dose of 2mg NG).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nasal Glucagon 1 mg</intervention_name>
    <arm_group_label>Nasal Glucagon 1 mg</arm_group_label>
    <other_name>Dry Powder Nasal Glucagon</other_name>
    <other_name>AMG504-1</other_name>
    <other_name>LY900018</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nasal Glucagon 2 mg</intervention_name>
    <arm_group_label>Nasal Glucagon 2 mg</arm_group_label>
    <other_name>Dry Powder Nasal Glucagon</other_name>
    <other_name>AMG504-1</other_name>
    <other_name>LY900018</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC Glucagon</intervention_name>
    <arm_group_label>SC Glucagon</arm_group_label>
    <other_name>Glucagon</other_name>
    <other_name>Glucagon for injection (rDNA origin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nasal Glucagon 3 mg</intervention_name>
    <arm_group_label>Nasal Glucagon 3 mg</arm_group_label>
    <other_name>Dry Powder Nasal Glucagon</other_name>
    <other_name>AMG504-1</other_name>
    <other_name>LY900018</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of type 1 diabetes between 2 and 30 years

          -  Receiving daily insulin injections or insulin pump therapy for at least 2 years

          -  If patient is taking Lantus, Levemir or equivalent once-daily in the evening as basal
             insulin, must be willing to transition to once-daily in the morning at least 48 hours
             prior to 1st dosing, and to follow this dosing regimen for the entire duration of the
             study

          -  Body mass index (BMI) greater than or equal to 20.00 and below or equal to 33.00 kg/m2

          -  Female patients must not be pregnant, and must be using effective contraception.

          -  Light-, non- or ex-smokers. A light smoker is defined as someone smoking 10 cigarettes
             or less per day for at least 3 months before day 1 of this study. An ex smoker is
             defined as someone who completely stopped smoking for at least 6 months before day 1
             of this study

        Exclusion Criteria:

          -  History of an episode of severe hypoglycemia (as defined by an episode that required
             third party assistance for treatment) in the previous 6 months before day 1 of this
             study

          -  Score ≥4 on the Clarke Hypoglycemia Awareness survey at screening

          -  Presence or history of pheochromocytoma (i.e. adrenal gland tumor)

          -  Presence or history of significant upper respiratory or allergic (i.e., seasonal
             rhinitis) disease

          -  Presence of clinically significant findings on nasal examination and bilateral
             anterior rhinoscopy

          -  Known presence of hereditary problems of galactose and /or lactose intolerance

          -  History of significant hypersensitivity to glucagon or any related products as well as
             severe hypersensitivity reactions (like angioedema) to any drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 15, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <results_first_submitted>March 18, 2013</results_first_submitted>
  <results_first_submitted_qc>August 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2014</results_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the clinical site's database and from participants who responded to advertising in local media.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group 1</title>
          <description>Nasal glucagon (NG) dose of 1 milligram (mg) and 2 mg. Subcutaneous (SC) glucagon dose of 1mg.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Group 2</title>
          <description>NG dose of 1 mg, 2 mg and 3mg. SC glucagon dose of 1mg.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Group 3</title>
          <description>NG dose of 2 mg and 3mg. SC glucagon dose of 1mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group 1</title>
          <description>NG dose of 1 mg and 2 mg. SC glucagon dose of 1mg.</description>
        </group>
        <group group_id="B2">
          <title>Treatment Group 2</title>
          <description>NG dose of 1 mg, 2 mg and 3mg. SC glucagon dose of 1mg.</description>
        </group>
        <group group_id="B3">
          <title>Treatment Group 3</title>
          <description>NG dose of 2 mg and 3mg. SC glucagon dose of 1mg.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="14"/>
                    <measurement group_id="B2" value="42" spread="2"/>
                    <measurement group_id="B3" value="25" spread="6"/>
                    <measurement group_id="B4" value="32" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Responders</title>
        <description>Participants with a blood glucose increment of ≥1.5 millimole per liter [mmol/L) within 15 of nadir (5 minutes post dose) and for at least 10 minutes following nadir.</description>
        <time_frame>Pre-dose; 30 minutes following glucagon administration</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>SC Glucagon</title>
            <description>SC glucagon injection 1 mg</description>
          </group>
          <group group_id="O2">
            <title>NG 1 mg</title>
            <description>NG dose of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>NG 2 mg</title>
            <description>NG dose of 2 mg</description>
          </group>
          <group group_id="O4">
            <title>NG 3 mg</title>
            <description>NG dose of 3 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders</title>
          <description>Participants with a blood glucose increment of ≥1.5 millimole per liter [mmol/L) within 15 of nadir (5 minutes post dose) and for at least 10 minutes following nadir.</description>
          <population>All enrolled participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least One Adverse Event</title>
        <description>Safety and tolerability evaluated through the assessment of adverse events. An AE was defined as any untoward medical occurrence in a clinical investigation subject administered the investigational product and which did not necessarily have a causal relationship with this treatment. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
        <time_frame>Within 3 hours post glucagon administration</time_frame>
        <population>Participants who received at least one dose of glucagon (SC Glucagon or NG).</population>
        <group_list>
          <group group_id="O1">
            <title>SC Glucagon</title>
            <description>SC glucagon injection 1 mg</description>
          </group>
          <group group_id="O2">
            <title>NG 1 mg</title>
            <description>NG dose of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>NG 2 mg</title>
            <description>NG dose of 2 mg</description>
          </group>
          <group group_id="O4">
            <title>NG 3 mg</title>
            <description>NG dose of 3 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Adverse Event</title>
          <description>Safety and tolerability evaluated through the assessment of adverse events. An AE was defined as any untoward medical occurrence in a clinical investigation subject administered the investigational product and which did not necessarily have a causal relationship with this treatment. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
          <population>Participants who received at least one dose of glucagon (SC Glucagon or NG).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) of Baseline-Adjusted Glucose</title>
        <time_frame>Pre-dose; 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
        <population>Participants who received at least one dose of glucagon (SC Glucagon or NG).</population>
        <group_list>
          <group group_id="O1">
            <title>SC Glucagon</title>
            <description>SC glucagon injection 1 mg</description>
          </group>
          <group group_id="O2">
            <title>NG 1 mg</title>
            <description>NG dose of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>NG 2 mg</title>
            <description>NG dose of 2 mg</description>
          </group>
          <group group_id="O4">
            <title>NG 3 mg</title>
            <description>NG dose of 3 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Baseline-Adjusted Glucose</title>
          <population>Participants who received at least one dose of glucagon (SC Glucagon or NG).</population>
          <units>millimole per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" spread="2.57"/>
                    <measurement group_id="O2" value="2.41" spread="1.89"/>
                    <measurement group_id="O3" value="3.46" spread="1.44"/>
                    <measurement group_id="O4" value="3.11" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose</title>
        <time_frame>Pre-dose; 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
        <population>Participants who received at least one dose of glucagon (SC Glucagon or NG).</population>
        <group_list>
          <group group_id="O1">
            <title>SC Glucagon</title>
            <description>SC glucagon injection 1 mg</description>
          </group>
          <group group_id="O2">
            <title>NG 1 mg</title>
            <description>NG dose of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>NG 2 mg</title>
            <description>NG dose of 2 mg</description>
          </group>
          <group group_id="O4">
            <title>NG 3 mg</title>
            <description>NG dose of 3 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose</title>
          <population>Participants who received at least one dose of glucagon (SC Glucagon or NG).</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.5" upper_limit="3.0"/>
                    <measurement group_id="O2" value="0.67" lower_limit="0.08" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.5" upper_limit="3.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.5" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Change From Baseline Concentration (Cmax) of Glucagon</title>
        <time_frame>Pre-dose; 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
        <population>Participants who received at least one dose of glucagon (SC Glucagon or NG) with available pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>SC Glucagon</title>
            <description>SC glucagon injection 1 mg</description>
          </group>
          <group group_id="O2">
            <title>NG 1 mg</title>
            <description>NG dose of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>NG 2 mg</title>
            <description>NG dose of 2 mg</description>
          </group>
          <group group_id="O4">
            <title>NG 3 mg</title>
            <description>NG dose of 3 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Change From Baseline Concentration (Cmax) of Glucagon</title>
          <population>Participants who received at least one dose of glucagon (SC Glucagon or NG) with available pharmacokinetic data.</population>
          <units>picograms per millilitre (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3930" spread="2650"/>
                    <measurement group_id="O2" value="504" spread="342"/>
                    <measurement group_id="O3" value="2370" spread="1810"/>
                    <measurement group_id="O4" value="1360" spread="722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon</title>
        <time_frame>Pre-dose; 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
        <population>Participants who received at least one dose of glucagon (SC Glucagon or NG) with available pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>SC Glucagon</title>
            <description>SC glucagon injection 1 mg</description>
          </group>
          <group group_id="O2">
            <title>NG 1 mg</title>
            <description>NG dose of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>NG 2 mg</title>
            <description>NG dose of 2 mg</description>
          </group>
          <group group_id="O4">
            <title>NG 3 mg</title>
            <description>NG dose of 3 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon</title>
          <population>Participants who received at least one dose of glucagon (SC Glucagon or NG) with available pharmacokinetic data.</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.08" upper_limit="0.67"/>
                    <measurement group_id="O2" value="0.25" lower_limit="0.17" upper_limit="0.25"/>
                    <measurement group_id="O3" value="0.33" lower_limit="0.17" upper_limit="0.50"/>
                    <measurement group_id="O4" value="0.29" lower_limit="0.17" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC0-last) of Baseline Adjusted Glucagon</title>
        <time_frame>Pre-dose; 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
        <population>Participants who received at least one dose of glucagon (SC Glucagon or NG) with available pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>SC Glucagon</title>
            <description>SC glucagon injection 1 mg</description>
          </group>
          <group group_id="O2">
            <title>NG 1 mg</title>
            <description>NG dose of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>NG 2 mg</title>
            <description>NG dose of 2 mg</description>
          </group>
          <group group_id="O4">
            <title>NG 3 mg</title>
            <description>NG dose of 3 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC0-last) of Baseline Adjusted Glucagon</title>
          <population>Participants who received at least one dose of glucagon (SC Glucagon or NG) with available pharmacokinetic data.</population>
          <units>hour*picogram per millilitre (hr*pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2390" spread="1350"/>
                    <measurement group_id="O2" value="95.2" spread="38.4"/>
                    <measurement group_id="O3" value="886" spread="796"/>
                    <measurement group_id="O4" value="720" spread="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug (Day 1) until post-study completion (Day 38)</time_frame>
      <desc>All enrolled participants who received at least one dose of glucagon (SC Glucagon or NG).</desc>
      <group_list>
        <group group_id="E1">
          <title>SC Glucagon</title>
          <description>SC glucagon injection 1 mg</description>
        </group>
        <group group_id="E2">
          <title>NG 1 mg</title>
          <description>NG dose of 1 mg</description>
        </group>
        <group group_id="E3">
          <title>NG 2 mg</title>
          <description>NG dose of 2 mg</description>
        </group>
        <group group_id="E4">
          <title>NG 3 mg</title>
          <description>NG dose of 3 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ocular Hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Catheter Site Bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Catheter Site Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Bruise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in Jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinus Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasal Dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasal Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cold Sweat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

